Track 3: Lipid and Metabolic Syndrome

Metabolic syndrome is the major cause that contribute to cardiovascular morbidity and mortality. It is a cluster of metabolic disorders, such as dyslipidemia, abdominal obesity, hypertension and impaired fasting glucose which will increase the risk for cardiovascular disease. The dietary lipids are also recognized to contribute in the development and the prevention of cardiovascular risk clustering. This review explores the relevant mechanisms involved in the influence of dietary fatty acids on metabolic syndrome components.

The important features for metabolic syndrome include hypertension (high blood pressure), insulin resistance, abnormal cholesterol, and an increased risk for clotting. People diagnosed with this syndrome are usually overweight or obese. When it comes to assessing the risk of cardiovascular disease, triglycerides also play a important role due to which dietary advice for people with heart problems usually aims at reducing blood cholesterol especially LDL cholesterol. Therefore, replacing saturated fat with polyunsaturated and monounsaturated fats, and increasing the intake of food products rich in fiber and complex carbohydrates such as whole grains, is usually recommended.

The development of metabolic syndrome mainly due to Genetics and the environmental factors. Approximately 20%-30% of the population in industrialized countries has metabolic syndrome and the people with Metabolic syndrome will have three times higher risk of developing cardiovascular disease. Additionally, statin drugs play a key role in the treatment of people with coronary heart disease, mostly because they lower LDL cholesterol.

The treatment choices include changing lifestyle and weight reduction which usually requires a specifically tailored, multifaceted program that includes diet and exercise. Medications also may be useful.

To submit the abstract under this track: Click Here.
E-mail us at cardiology@expertscongress.com or cardiology2018@gmail.com 
 Submit the abstarct soon. All accepted abstracts will be provided with partial sponsorship upto July 17, 2018. 
Contact us to know more.